Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Gastrectomy | Research

Oncological risk of proximal gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy

Authors: Yonghe Chen, Xiaojiang Chen, Yi Lin, Shenyan Zhang, Zhiwei Zhou, Junsheng Peng

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Purpose

This study assesses the metastasis rate of the key distal lymph nodes (KDLN) that are not routinely dissected in proximal gastrectomy, aiming to explore the oncological safety of proximal gastrectomy for upper gastric cancer who underwent neoadjuvant chemotherapy.

Methods

We analyzed a cohort of 150 patients with proximal locally advanced gastric cancer (cT3/4 before chemotherapy) from two high-volume cancer centers in China who received preoperative neoadjuvant chemotherapy (NAC) and total gastrectomy with lymph node dissection. Metastasis rate of the KDLN (No.5/6/12a) and the risk factors were analyzed.

Results

Key distal lymph node metastasis was detected in 10% (15/150) of patients, with a metastasis rate of 6% (9/150) in No. 5 lymph nodes, 6.7% (10/150) in No. 6 lymph nodes, and 2.7% (2/75) in No. 12a lymph nodes. The therapeutic value index of KDLN as one entity is 5.8. Tumor length showed no correlation with KDLN metastasis, while tumor regression grade (TRG) emerged as an independent risk factor (OR: 1.47; p-value: 0.04). Of those with TRG3 (no response to NAC), 80% (12/15) was found with KDLN metastasis.

Conclusion

For cT3/4 proximal locally advanced gastric cancer patients, the risk of KDLN metastasis remains notably high even after NAC. Therefore, proximal gastrectomy is not recommended; instead, total gastrectomy with thorough distal lymphadenectomy is the preferred surgical approach.
Literature
1.
Xie Y, Shi L, He X, Luo Y. Gastrointestinal cancers in China, the USA, and Europe. Gastroenterol Rep (Oxf). 2021;9:91–104.CrossRefPubMed
2.
Japanese Gastric Cancer Association. Japanese gastric Cancer Treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1–25.CrossRef
3.
Fujiya K, Kawamura T, Omae K, Makuuchi R, Irino T, Tokunaga M, et al. Impact of Malnutrition after Gastrectomy for Gastric Cancer on Long-Term Survival. Ann Surg Oncol. 2018;25:974–83.CrossRefPubMed
4.
Takiguchi N, Takahashi M, Ikeda M, Inagawa S, Ueda S, Nobuoka T, et al. Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45): a nationwide multi-institutional study. Gastric Cancer. 2015;18:407–16.CrossRefPubMed
5.
Ri M, Kumagai K, Namikawa K, Atsumi S, Hayami M, Makuuchi R, et al. Is proximal gastrectomy indicated for locally advanced cancer in the upper third of the stomach? Ann Gastroenterol Surg. 2021;5:767–75.CrossRefPubMedPubMedCentral
6.
Yura M, Yoshikawa T, Otsuki S, Yamagata Y, Morita S, Katai H, et al. Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer. Gastric Cancer. 2019;22:1029–35.CrossRefPubMed
7.
Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60.CrossRefPubMed
8.
Wang X, Zhao L, Liu H, Zhong D, Liu W, Shan G, et al. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer. 2016;114:1326–33.CrossRefPubMedPubMedCentral
9.
Hosoda K, Azuma M, Katada C, Moriya H, Mieno H, Ishido K, et al. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. Gastric Cancer. 2019;22:598–606.CrossRefPubMed
10.
Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12:6–22.CrossRefPubMed
11.
Hasegawa S, Yoshikawa T, Shirai J, Fujikawa H, Cho H, Doiuchi T, et al. A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multidetector-row CT. Ann Surg Oncol. 2013;20:2016–22.CrossRefPubMed
12.
Kim JW, Shin SS, Heo SH, Choi YD, Lim HS, Park YK, et al. Diagnostic performance of 64-section CT using CT gastrography in preoperative T staging of gastric cancer according to 7th edition of AJCC cancer staging manual. Eur Radiol. 2012;22:654–62.CrossRefPubMed
13.
Kim TU, Kim S, Lee JW, Lee NK, Jeon TY, Park DY. MDCT features in the differentiation of T4a gastric cancer from less-advanced gastric cancer: significance of the hyperattenuating serosa sign. Br J Radiol. 2013;86:20130290.CrossRefPubMedPubMedCentral
14.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.CrossRefPubMed
15.
Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82:346–51.CrossRefPubMed
16.
Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Mansfield P, et al. Tumor Regression Grade in Gastric Cancer after Preoperative Therapy. J Gastrointest Surg. 2021;25:1380–7.CrossRefPubMed
17.
Sinnamon AJ, Savoldy M, Mehta R, Dineen SP, Peña LR, Lauwers GY, et al. Tumor Regression Grade and overall survival following Gastrectomy with preoperative therapy for gastric Cancer. Ann Surg Oncol. 2023;30:3580–9.CrossRefPubMed
18.
Kim DH, Choi MG, Noh JH, Sohn TS, Bae JM, Kim S. Clinical significance of skip lymph node metastasis in gastric cancer patients. Eur J Surg Oncol. 2015;41:339–45.CrossRefPubMed
19.
Li GZ, Doherty GM, Wang J. Surgical Management of Gastric Cancer: a review. JAMA Surg. 2022;157:446–54.CrossRefPubMed
20.
Fh W, Xt Z, Yf L, L T, Xj Q, Je Y et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer communications (London, England). 2021;41.
21.
Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:167–92.CrossRefPubMed
22.
Park DJ, Han S-U, Hyung WJ, Hwang S-H, Hur H, Yang H-K, et al. Effect of laparoscopic proximal gastrectomy with double-Tract Reconstruction vs total gastrectomy on hemoglobin level and vitamin B12 supplementation in Upper-Third Early gastric Cancer: a Randomized Clinical Trial. JAMA Netw Open. 2023;6:e2256004.CrossRefPubMedPubMedCentral
23.
Hirata Y, Kim H-I, Grotz TE, Matsuda S, Badgwell BD, Ikoma N. The role of proximal gastrectomy in gastric cancer. Chin Clin Oncol. 2022;11:39.CrossRefPubMed
24.
Peng R, Yue C, Wei W, Zhou B, Wen X, Gu R-M, et al. Proximal gastrectomy may be a reasonable choice for patients with selected proximal advanced gastric cancer: a propensity score-matched analysis. Asian J Surg. 2022;45:1823–31.CrossRefPubMed
25.
Lee S, Son WJ, Roh YH, Song JH, Park SH, Cho M, et al. Indication of Proximal Gastrectomy for Advanced Proximal Gastric Cancer based on Lymph Node Metastasis at the distal part of the stomach. Ann Surg Open. 2021;2:e107.CrossRefPubMedPubMedCentral
26.
Wang F-H, Zhang X-T, Li Y-F, Tang L, Qu X-J, Ying J-E, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021;41:747–95.CrossRefPubMed
27.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed
28.
Coccolini F, Nardi M, Montori G, Ceresoli M, Celotti A, Cascinu S, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018;51:120–7.CrossRefPubMed
29.
Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.CrossRefPubMed
30.
Kaltenmeier C, Althans A, Mascara M, Nassour I, Khan S, Hoehn R, et al. Pathologic complete response following neoadjuvant therapy for gastric adenocarcinoma: a National Cancer Database Analysis on Incidence, Predictors, and outcomes. Am Surg. 2021;87:1145–54.CrossRefPubMed
31.
Sah BK, Zhang B, Zhang H, Li J, Yuan F, Ma T, et al. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020;11:6093.ADSCrossRefPubMedPubMedCentral
Metadata
Title
Oncological risk of proximal gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy
Authors
Yonghe Chen
Xiaojiang Chen
Yi Lin
Shenyan Zhang
Zhiwei Zhou
Junsheng Peng
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11993-5

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Downregulation of PTPRT elevates the expression of survivin and promotes the proliferation, migration, and invasion of lung adenocarcinoma

Correction

Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

Research

Transcriptomics analysis revealed that TAZ regulates the proliferation of KIRC cells through mitophagy

Research

All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells

Correspondence

Using administrative registries as a source for population-based cancer incidence and mortality

Research

Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits